overall survival

CHICAGO, Ill., May 29, 2026 Johnson & Johnson has announced encouraging long-term results from the Phase 1/1b CHRYSALIS-2 study,...

Rahway, N.J., USA – May 18, 2026 Merck announced that its pivotal Phase 3 TroFuse-005 clinical trial evaluating sacituzumab...

REDWOOD CITY, Calif., December 8, 2025 — Coherus Oncology today announced compelling six-year overall survival (OS) follow-up data from...